MY171526A - Pharmaceutical formulation for reducing frequency of urination and method of use thereof - Google Patents

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Info

Publication number
MY171526A
MY171526A MYPI2015700161A MYPI2015700161A MY171526A MY 171526 A MY171526 A MY 171526A MY PI2015700161 A MYPI2015700161 A MY PI2015700161A MY PI2015700161 A MYPI2015700161 A MY PI2015700161A MY 171526 A MY171526 A MY 171526A
Authority
MY
Malaysia
Prior art keywords
urination
pharmaceutical formulation
reducing frequency
frequency
reducing
Prior art date
Application number
MYPI2015700161A
Other languages
English (en)
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MY171526A publication Critical patent/MY171526A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2015700161A 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof MY171526A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
MY171526A true MY171526A (en) 2019-10-16

Family

ID=49997724

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015700161A MY171526A (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Country Status (16)

Country Link
US (3) US20160022615A1 (cg-RX-API-DMAC10.html)
EP (3) EP3527204A1 (cg-RX-API-DMAC10.html)
JP (4) JP2015522659A (cg-RX-API-DMAC10.html)
KR (2) KR20150048740A (cg-RX-API-DMAC10.html)
CN (4) CN104470522A (cg-RX-API-DMAC10.html)
AU (3) AU2013293489B2 (cg-RX-API-DMAC10.html)
BR (2) BR112014031306A2 (cg-RX-API-DMAC10.html)
CA (2) CA2879640A1 (cg-RX-API-DMAC10.html)
HK (4) HK1205931A1 (cg-RX-API-DMAC10.html)
IL (3) IL236028A0 (cg-RX-API-DMAC10.html)
MX (2) MX2015001188A (cg-RX-API-DMAC10.html)
MY (1) MY171526A (cg-RX-API-DMAC10.html)
RU (3) RU2015106672A (cg-RX-API-DMAC10.html)
SG (2) SG11201500578VA (cg-RX-API-DMAC10.html)
WO (2) WO2014018222A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201408993B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054655A (ko) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
MX2019004191A (es) * 2017-11-07 2020-02-12 Poviva Tea Llc Composiciones de alimentos y bebidas que comprenden inhibidores de pde5.
TW202302086A (zh) 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040921B (en) * 1998-12-23 2005-12-30 Alza Corporation Dosage forms comprising porous particles
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
EP1313478A2 (en) * 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
EP1437344A4 (en) * 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZENE DERIVATIVES AND PROCESS FOR THE PREPARATION AND USE THEREOF
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2004043365A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2009021007A1 (en) * 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
SG11201500578VA (en) 2015-03-30
JP2015522658A (ja) 2015-08-06
AU2013293489B2 (en) 2017-09-07
HK1246203A1 (zh) 2018-09-07
JP2018039831A (ja) 2018-03-15
AU2013293488B2 (en) 2018-05-17
CN107335057A (zh) 2017-11-10
IL236028A0 (en) 2015-01-29
AU2018208765A1 (en) 2018-08-16
RU2015106762A (ru) 2016-09-20
JP2015522659A (ja) 2015-08-06
CN107661326A (zh) 2018-02-06
US20180344674A1 (en) 2018-12-06
US20160022615A1 (en) 2016-01-28
HK1205931A1 (en) 2015-12-31
IL261232A (en) 2018-10-31
CN104540505A (zh) 2015-04-22
JP2018127482A (ja) 2018-08-16
MX2015001188A (es) 2015-05-07
BR112014031306A2 (pt) 2017-06-27
MX2015001190A (es) 2015-05-07
KR20150048740A (ko) 2015-05-07
WO2014018223A1 (en) 2014-01-30
HK1250628A1 (zh) 2019-01-11
US20170100351A1 (en) 2017-04-13
EP2844241A1 (en) 2015-03-11
ZA201408993B (en) 2016-09-28
BR112015001627A2 (pt) 2017-07-04
CA2879640A1 (en) 2014-01-03
AU2013293488A2 (en) 2015-02-26
EP2877179A1 (en) 2015-06-03
IL236622A0 (en) 2015-02-26
RU2019101864A (ru) 2019-03-11
WO2014018222A1 (en) 2014-01-30
EP3527204A1 (en) 2019-08-21
EP2877179A4 (en) 2016-03-02
ZA201500459B (en) 2016-09-28
KR20150048741A (ko) 2015-05-07
CN104470522A (zh) 2015-03-25
AU2013293489A1 (en) 2015-03-12
RU2015106672A (ru) 2016-09-20
HK1205932A1 (en) 2015-12-31
AU2013293488A1 (en) 2015-02-19
CA2875818A1 (en) 2014-01-30
EP2844241A4 (en) 2015-04-29
SG11201500601QA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2014CN00568A (cg-RX-API-DMAC10.html)
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
IN2014DN10386A (cg-RX-API-DMAC10.html)
SG184222A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
HRP20180924T1 (hr) Sastavi za transdermalnu administraciju aktivnih sastojaka
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
BR112014016550A8 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
IN2014MN02269A (cg-RX-API-DMAC10.html)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX339196B (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
IN2015DN00966A (cg-RX-API-DMAC10.html)
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
IN2014DN09359A (cg-RX-API-DMAC10.html)